盤中異動 | 石藥集團盤中下跌5%,報於9.03港元
2022年2月24日13時2分,石藥集團(HK01093)盤中下跌5%,報於9.03港元,成交額達1.3億港元,換手率達到0.11%。
2月9日訊,石藥集團(01093.HK)公佈,已完成向獨立第三方收購有限合夥企業珠海至凡的100%權益,後者目前持有廣州銘康生物51%權益,對價1.54億人民幣。
2月10日,光大證券:石藥集團(01093)當前估值具吸引力,維持“買入”評級。1月24日,光大證券:維持石藥集團(01093),“買入”評級,股權激勵激發活力。1月13日,中泰國際:重申石藥集團(01093)“買入”評級,目標價12.72港元。
最新的財務數據顯示,公司於2021年3季度,營業收入68.19億人民幣,淨利潤12.88億人民幣;營業收入同比增加2.93%,毛利潤同比增加2.24%,淨利潤同比增加5.17%。
盈立趨勢長盈模型最近一次交易信號,2022年2月10日出現關注信號,觸發價格爲9.82港元(信號僅供參考)。
uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.